liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prevalence of the apolipoprotein E epsilon 4 allele in amyloid beta positive subjects across the spectrum of Alzheimers disease
Lund Univ, Sweden.
Vrije Univ Amsterdam, Netherlands; Vrije Univ Amsterdam, Netherlands.
Maastricht Univ, Netherlands.
Univ Calif Berkeley, CA 94720 USA.
Show others and affiliations
2018 (English)In: Alzheimer's & Dementia, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 14, no 7, p. 913-924Article in journal (Refereed) Published
Abstract [en]

Introduction: Apolipoprotein E (APOE) epsilon 4 is the major genetic risk factor for Alzheimers disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid beta(A beta) pathology. Methods: We included 3451 A beta+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE epsilon 4 prevalence in relation to age, sex, education, and geographical location. Results: The APOE epsilon 4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in A beta+ cognitively normal and A beta+ mild cognitive impairment (P amp;lt;.05) but not in A beta+ AD dementia (P =.66). The prevalence was highest in Northern Europe but did not vary by sex or education. Discussion: The APOE E4 prevalence in AD was higher than that in previous studies, which did not require presence of A beta pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location. (C) 2018 the Alzheimers Association. Published by Elsevier Inc. All rights reserved.

Place, publisher, year, edition, pages
ELSEVIER SCIENCE INC , 2018. Vol. 14, no 7, p. 913-924
Keywords [en]
APOE; Prevalence; Amyloid; PET; CSF; Alzheimers disease; Mild cognitive impairment; Subjective cognitive decline; Age; Sex; Education; Geographical location
National Category
Geriatrics
Identifiers
URN: urn:nbn:se:liu:diva-150288DOI: 10.1016/j.jalz.2018.02.009ISI: 000438783200009PubMedID: 29601787OAI: oai:DiVA.org:liu-150288DiVA, id: diva2:1239663
Note

Funding Agencies|AXA Research Fund; Fondation Universite Pierre et Marie Curie; "Fondation pour la Recherche sur Alzheimer", Paris, France; program "Investissements davenir" [ANR-10-IAIHU-06]; National Institutes of Health [P50 AG005133, RF1 AG025516, PO1 AG025204]; Marie Curie FP7 International Outgoing Fellowship [628812]; Instituto de Salud Carlos III (Fondo de InvestigaciOn Sanitario) [PI08/0139, PI12/02288, PI16/01652]; NIH/NIA [RF1 AG057570, AG035137, AG032554, AG022374, AG13616, AG12101, AG08051, NIH-HLB HL111724]; Instituto de Salud Carlos III (CIBERNED program)

Available from: 2018-08-17 Created: 2018-08-17 Last updated: 2018-08-17

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Marcusson, Jan
By organisation
Division of Neuro and Inflammation ScienceFaculty of Medicine and Health SciencesDepartment of Acute Internal Medicine and Geriatrics
In the same journal
Alzheimer's & Dementia
Geriatrics

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 67 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf